STRATEGIC NEWS WATCH — September 3, 2026
|
Ivonescimab’s survival win over Keytruda came China-only, even as its global trial has already missed on interim PFS, leading a day that also delivered AbbVie’s myeloma bispecific, Ultragenyx’s near-halving, and two more nine-figure delivery-and-conjugate deals. Today’s top developments:
|
What to Watch
- HARMONI-3 over HARMONI-2 — The China-only survival win is not the dataset a Western filing rests on. The full HARMONI-3 readout is the tell — whether the non-squamous cohort separates where squamous did not, alongside Summit’s November 14 PDUFA in previously treated EGFR-mutated NSCLC.
- Etentamig’s survival boundary — A 12-month overall survival of 87.9% against 72% is numerically favorable but formally unproven. The open question is whether longer follow-up crosses the boundary, and whether regulators accept response rate and progression-free survival alone in a field already holding three approved BCMA options.
- Ultragenyx’s Aurora read-through — With the company reviewing program disposition and cutting expenses, the question now is whether the Aurora study in other Angelman genotypes survives, and whether GENGLYCOS confirmatory-evidence progress becomes the stated priority.
- What Novartis actually committed — Option fees, milestones and royalties were all undisclosed and no candidate products named. Alteogen’s filings are where the option-exercise economics should emerge, the only place the real number is likely to surface.
- HMPL-A830 entering the clinic — The first antibody-delivered KRAS inhibitor is due to start trials before year-end, with HUTCHMED running global Phase 1. The tolerability profile is what to track, since it is the entire premise of conjugating a KRAS inhibitor rather than dosing it systemically.
This brief highlights the edition’s top stories. Read the full September 3, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.